Fen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fen Wang has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Feng Liu
Department of Neurology The Second Affiliated Hospital of Soochow University Suzhou Jiangsu China
20 shared publications - Cheng-Jie Mao
Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China
7 shared publications Chun-Feng Liu
Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, China
7 shared publicationsJun-Yi Liu
Soochow University
5 shared publicationsQian-Kun Lv
Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
5 shared publicationsCheng-Jie Mao
Department of Neurology and Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
4 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Elsevier in Journal of Advanced Research
Sleep deprivation accelerates Parkinson’s disease pathology by upregulating LAG3 in astrocytes and disrupting glymphatic system function
- 13 April 2026
- Published by Elsevier in Journal of Advanced Research
Open AccessSleep deprivation accelerates Parkinson’s disease pathology by upregulating LAG3 in astrocytes and disrupting glymphatic system function
- Open Access
- 25 November 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Regulation of mitochondrial dynamics and function by melatonin type 1 receptor in parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease characterized by dopaminergic neuron loss and Lewy bodies in the substantia nigra. Abnormal mitochondrial function and accumulated α-synuclein (α-syn) are key etiological factors of PD. Melatonin type 1 receptor (MT1) regulates sleep upon activation by melatonin and may be reduced in PD patients. However, the role of MT1 in PD pathogenesis remains elusive. In this study, we found knockdown of MT1 caused mitochondrial dysfunction, mitochondrial fission and mitophagy in SH-SY5Y cells. Expression of mitochondrial fission protein dynamin-related protein 1 (DRP1) was increased and expression of fusion proteins optic atrophy 1 (OPA1), mitofusin 1 (MFN1) and mitofusin 2 (MFN2) were decreased. This was probably attributed to decreased phosphorylation of DRP1 at S637 by protein kinase A (PKA) and increased phosphorylation at S616 by extracellular-regulated kinase 1/2 (ERK1/2). Loss of MT1 exacerbated mitochondrial fission without influencing mitophagy, TH expression and movement in an MPTP-induced mouse model. Neuronal MT1 deficiency aggravated preformed fibrils induced autophagy inhibition and α-syn aggregation. Overexpression of MT1 reduced mitochondrial fission, increased LC3II expression and decreased P62 accumulation to promote autophagy in HEK293T cells, thus mitigating aggregation of α-syn. This study demonstrates the function of MT1 in mitochondria and autophagy, which sheds further light on PD prevention targeting MT1.
- 25 November 2025
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 83 (1)
Open AccessRegulation of mitochondrial dynamics and function by melatonin type 1 receptor in parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease characterized by dopaminergic neuron loss and Lewy bodies in the substantia nigra. Abnormal mitochondrial function and accumulated α-synuclein (α-syn) are key etiological factors of PD. Melatonin type 1 receptor (MT1) regulates sleep upon activation by melatonin and may be reduced in PD patients. However, the role of MT1 in PD pathogenesis remains elusive. In this study, we found knockdown of MT1 caused mitochondrial dysfunction, mitochondrial fission and mitophagy in SH-SY5Y cells. Expression of mitochondrial fission protein dynamin-related protein 1 (DRP1) was increased and expression of fusion proteins optic atrophy 1 (OPA1), mitofusin 1 (MFN1) and mitofusin 2 (MFN2) were decreased. This was probably attributed to decreased phosphorylation of DRP1 at S637 by protein kinase A (PKA) and increased phosphorylation at S616 by extracellular-regulated kinase 1/2 (ERK1/2). Loss of MT1 exacerbated mitochondrial fission without influencing mitophagy, TH expression and movement in an MPTP-induced mouse model. Neuronal MT1 deficiency aggravated preformed fibrils induced autophagy inhibition and α-syn aggregation. Overexpression of MT1 reduced mitochondrial fission, increased LC3II expression and decreased P62 accumulation to promote autophagy in HEK293T cells, thus mitigating aggregation of α-syn. This study demonstrates the function of MT1 in mitochondria and autophagy, which sheds further light on PD prevention targeting MT1.
- Open Access
- 29 July 2025
- Published by Springer Nature in Research Square
Regulation of mitochondrial dynamics and function by MT1 melatonin receptor in Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease characterized by dopaminergic neurons loss and Lewy body presence in the substantia nigra. Abnormal mitochondrial function and accumulated alpha-synuclein (α-syn) are key etiology of PD. Melatonin type receptor 1 (MT1) regulates sleep upon activation by melatonin and is suggested to decrease in PD patients. However, the role of MT1 in PD pathogenesis remains elusive. In this study, we knocked down MT1 in SH-SY5Y neuroblastoma cells and found MT1 loss caused mitochondria dysfunction. Moreover, live cell imaging of MitoTracker staining and transmission electron microscope (TEM) proved that MT1 knockdown affected mitochondria morphology. The expression of mitochondria fission protein DRP1 was increased and the fusion protein OPA1, MFN1 and MFN2 was decreased. This is probably attributed to the declined phosphorylation of DRP1 at S637 by PKA and increased phosphorylation at S616 by ERK1/2. Moreover, MT1 knockdown also impaired mitophagy, manifested by declined PINK1 and Parkin. In a MPTP induced PD mouse model, MT1 deficiency altered the mitochondria fission through the same mechanism as in vitro but did not impair mitophagy, tyrosine hydroxylase (TH) expression and mice movement. However, MPTP induced autophagy inhibition was exacerbated in MT1 KO mice. Neuronal MT1 deficiency aggravated preformed fibrils (PFFs) induced autophagy inhibition and α-syn aggregation. Overexpression of MT1 reduced mitochondria fission, as well as increased LC3-II expression and decreased P62 accumulation to promote autophagy in HEK293T cells, thus mitigating the aggregation of α-syn. Autophagy flux indicated by mCherry-LC3-II-EGFP fluorescence was also enhanced after MT1 overexpression. Together, our study demonstrates the function of MT1 in mitochondria and autophagy, which sheds further light on PD prevention targeting MT1.
- 29 July 2025
- Published by Springer Nature in Research Square
Open AccessRegulation of mitochondrial dynamics and function by MT1 melatonin receptor in Parkinson’s disease
Parkinson’s disease (PD) is a neurodegenerative disease characterized by dopaminergic neurons loss and Lewy body presence in the substantia nigra. Abnormal mitochondrial function and accumulated alpha-synuclein (α-syn) are key etiology of PD. Melatonin type receptor 1 (MT1) regulates sleep upon activation by melatonin and is suggested to decrease in PD patients. However, the role of MT1 in PD pathogenesis remains elusive. In this study, we knocked down MT1 in SH-SY5Y neuroblastoma cells and found MT1 loss caused mitochondria dysfunction. Moreover, live cell imaging of MitoTracker staining and transmission electron microscope (TEM) proved that MT1 knockdown affected mitochondria morphology. The expression of mitochondria fission protein DRP1 was increased and the fusion protein OPA1, MFN1 and MFN2 was decreased. This is probably attributed to the declined phosphorylation of DRP1 at S637 by PKA and increased phosphorylation at S616 by ERK1/2. Moreover, MT1 knockdown also impaired mitophagy, manifested by declined PINK1 and Parkin. In a MPTP induced PD mouse model, MT1 deficiency altered the mitochondria fission through the same mechanism as in vitro but did not impair mitophagy, tyrosine hydroxylase (TH) expression and mice movement. However, MPTP induced autophagy inhibition was exacerbated in MT1 KO mice. Neuronal MT1 deficiency aggravated preformed fibrils (PFFs) induced autophagy inhibition and α-syn aggregation. Overexpression of MT1 reduced mitochondria fission, as well as increased LC3-II expression and decreased P62 accumulation to promote autophagy in HEK293T cells, thus mitigating the aggregation of α-syn. Autophagy flux indicated by mCherry-LC3-II-EGFP fluorescence was also enhanced after MT1 overexpression. Together, our study demonstrates the function of MT1 in mitochondria and autophagy, which sheds further light on PD prevention targeting MT1.
- Top Cited PapersOpen Access
- 6 January 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 205, 106791
New perspectives on the glymphatic system and the relationship between glymphatic system and neurodegenerative diseases
- 6 January 2025
- Published by Elsevier in Neurobiology of Disease
- Vol. 205, 106791
Top Cited PapersOpen AccessNew perspectives on the glymphatic system and the relationship between glymphatic system and neurodegenerative diseases
- Open Access
- 23 October 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (10) , e70088
Microglial Melatonin Receptor 1 Degrades Pathological Alpha‐Synuclein Through Activating LC3‐Associated Phagocytosis In Vitro
Aims: Parkinson's disease (PD) is characterized by the formation of Lewy bodies (LBs), primarily constituted of α‐synuclein (α‐Syn). Microglial cells exhibit specific reactivity toward misfolded proteins such as α‐Syn. However, the exact clearance mechanism and related molecular targets remain elusive.Methods: BV2 cells, primary microglia from wild‐type and MT1 knockout mice, and primary cortical neurons were utilized as experimental models. The study investigated relevant mechanisms by modulating microglial MT1 expression through small RNA interference (RNAi) and lentiviral overexpression techniques. Furthermore, pathological aggregation of α‐Syn was induced using pre‐formed fibrils (PFF) α‐Syn. Co‐immunoprecipitation, immunofluorescence, Western blot (WB), and quantitative real‐time PCR were used to elucidate the mechanisms of molecular regulation.Results: In this study, we elucidated the regulatory role of the melatonin receptor 1 (MT1) in the microglial phagocytic process. Following MT1 knockout, the ability of microglial cells to engulf latex beads and zymosan particles decreased, subsequently affecting the phagocytic degradation of fibrillar α‐Syn by microglial cells. Furthermore, the loss of MT1 receptors in microglial cells exacerbates the aggregation of α‐Syn in neurons induced by pre‐formed fibrils (PFF) α‐Syn. Mechanistically, MT1 influences the phagocytic function of microglial cells by regulating the Rubicon‐dependent LC3‐associated phagocytosis (LAP) pathway.Conclusion: Taken together, the results suggest the neuroprotective function of microglial cells in clearing α‐Syn through MT1‐mediated LAP, highlighting the potential key role of MT1 in pathogenic mechanisms associated with α‐Syn.
- 23 October 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (10) , e70088
Open AccessMicroglial Melatonin Receptor 1 Degrades Pathological Alpha‐Synuclein Through Activating LC3‐Associated Phagocytosis In Vitro
Aims: Parkinson's disease (PD) is characterized by the formation of Lewy bodies (LBs), primarily constituted of α‐synuclein (α‐Syn). Microglial cells exhibit specific reactivity toward misfolded proteins such as α‐Syn. However, the exact clearance mechanism and related molecular targets remain elusive.Methods: BV2 cells, primary microglia from wild‐type and MT1 knockout mice, and primary cortical neurons were utilized as experimental models. The study investigated relevant mechanisms by modulating microglial MT1 expression through small RNA interference (RNAi) and lentiviral overexpression techniques. Furthermore, pathological aggregation of α‐Syn was induced using pre‐formed fibrils (PFF) α‐Syn. Co‐immunoprecipitation, immunofluorescence, Western blot (WB), and quantitative real‐time PCR were used to elucidate the mechanisms of molecular regulation.Results: In this study, we elucidated the regulatory role of the melatonin receptor 1 (MT1) in the microglial phagocytic process. Following MT1 knockout, the ability of microglial cells to engulf latex beads and zymosan particles decreased, subsequently affecting the phagocytic degradation of fibrillar α‐Syn by microglial cells. Furthermore, the loss of MT1 receptors in microglial cells exacerbates the aggregation of α‐Syn in neurons induced by pre‐formed fibrils (PFF) α‐Syn. Mechanistically, MT1 influences the phagocytic function of microglial cells by regulating the Rubicon‐dependent LC3‐associated phagocytosis (LAP) pathway.Conclusion: Taken together, the results suggest the neuroprotective function of microglial cells in clearing α‐Syn through MT1‐mediated LAP, highlighting the potential key role of MT1 in pathogenic mechanisms associated with α‐Syn.
- 16 September 2024
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 40 (12) , 1901-1914
Melatonin Ameliorates Abnormal Sleep-Wake Behavior via Facilitating Lipid Metabolism in a Zebrafish Model of Parkinson’s Disease
Sleep-wake disorder is one of the most common nonmotor symptoms of Parkinson's disease (PD). Melatonin has the potential to improve sleep-wake disorder, but its mechanism of action is still unclear. Our data showed that melatonin only improved the motor and sleep-wake behavior of a zebrafish PD model when melatonin receptor 1 was present. Thus, we explored the underlying mechanisms by applying a rotenone model. After the PD zebrafish model was induced by 10 nmol/L rotenone, the motor and sleep-wake behavior were assessed. In situ hybridization and real-time quantitative PCR were used to detect the expression of melatonin receptors and lipid-metabolism-related genes. In the PD model, we found abnormal lipid metabolism, which was reversed by melatonin. This may be one of the main pathways for improving PD sleep-wake disorder.
- 16 September 2024
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 40 (12) , 1901-1914
Melatonin Ameliorates Abnormal Sleep-Wake Behavior via Facilitating Lipid Metabolism in a Zebrafish Model of Parkinson’s Disease
Sleep-wake disorder is one of the most common nonmotor symptoms of Parkinson's disease (PD). Melatonin has the potential to improve sleep-wake disorder, but its mechanism of action is still unclear. Our data showed that melatonin only improved the motor and sleep-wake behavior of a zebrafish PD model when melatonin receptor 1 was present. Thus, we explored the underlying mechanisms by applying a rotenone model. After the PD zebrafish model was induced by 10 nmol/L rotenone, the motor and sleep-wake behavior were assessed. In situ hybridization and real-time quantitative PCR were used to detect the expression of melatonin receptors and lipid-metabolism-related genes. In the PD model, we found abnormal lipid metabolism, which was reversed by melatonin. This may be one of the main pathways for improving PD sleep-wake disorder.
- 26 January 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (3) , 572-581
Inhibition of GluN2D-Containing NMDA Receptors Protects Dopaminergic Neurons against 6-OHDA-Induced Neurotoxicity via Activating ERK/NRF2/HO-1 Signaling
Abnormal glutamate signaling is implicated in the heightened vulnerability of dopaminergic neurons in Parkinson's disease (PD). NMDA receptors are ion-gated glutamate receptors with high calcium permeability, and their GluN2D subunits are prominently distributed in the basal ganglia and brainstem nuclei. Previous studies have reported that dopamine depletion led to the dysfunctions of GluN2D-containing NMDA receptors in PD animal models. However, it remains unknown whether selective modulation of GluN2D could protect dopaminergic neurons against neurotoxicity in PD. In this study, we found that allosteric activation of GluN2D-containing NMDA receptors decreased the cell viability of MES23.5 dopaminergic cells and the GluN2D inhibitor, QNZ46, showed antioxidant effects and significantly relieved apoptosis in 6-OHDA-treated cells. Meanwhile, we demonstrated that QNZ46 might act via activation of the ERK/NRF2/HO-1 pathway. We also verified that QNZ46 could rescue abnormal behaviors and attenuate dopaminergic cell loss in a 6-OHDA-lesioned rat model of PD. Although the precise mechanisms underlying the efficacy of QNZ46 in vivo remain elusive, the inhibition of the GluN2D subunit should be a considerable way to treat PD. More GluN2D-selective drugs, which present minimal side effects and broad therapeutic windows, need to be developed for PD treatment in future studies.
- 26 January 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (3) , 572-581
Inhibition of GluN2D-Containing NMDA Receptors Protects Dopaminergic Neurons against 6-OHDA-Induced Neurotoxicity via Activating ERK/NRF2/HO-1 Signaling
Abnormal glutamate signaling is implicated in the heightened vulnerability of dopaminergic neurons in Parkinson's disease (PD). NMDA receptors are ion-gated glutamate receptors with high calcium permeability, and their GluN2D subunits are prominently distributed in the basal ganglia and brainstem nuclei. Previous studies have reported that dopamine depletion led to the dysfunctions of GluN2D-containing NMDA receptors in PD animal models. However, it remains unknown whether selective modulation of GluN2D could protect dopaminergic neurons against neurotoxicity in PD. In this study, we found that allosteric activation of GluN2D-containing NMDA receptors decreased the cell viability of MES23.5 dopaminergic cells and the GluN2D inhibitor, QNZ46, showed antioxidant effects and significantly relieved apoptosis in 6-OHDA-treated cells. Meanwhile, we demonstrated that QNZ46 might act via activation of the ERK/NRF2/HO-1 pathway. We also verified that QNZ46 could rescue abnormal behaviors and attenuate dopaminergic cell loss in a 6-OHDA-lesioned rat model of PD. Although the precise mechanisms underlying the efficacy of QNZ46 in vivo remain elusive, the inhibition of the GluN2D subunit should be a considerable way to treat PD. More GluN2D-selective drugs, which present minimal side effects and broad therapeutic windows, need to be developed for PD treatment in future studies.
- 9 January 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 120, 106001
The association between plasma GPNMB and Parkinson's disease and multiple system atrophy
- 9 January 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 120, 106001
The association between plasma GPNMB and Parkinson's disease and multiple system atrophy
- 1 December 2023
- Published by Elsevier in Behavioural Brain Research
- Vol. 459, 114787
Safinamide alleviates hyperalgesia via inhibiting hyperexcitability of DRG neurons in a mouse model of Parkinson's disease
- 1 December 2023
- Published by Elsevier in Behavioural Brain Research
- Vol. 459, 114787
Safinamide alleviates hyperalgesia via inhibiting hyperexcitability of DRG neurons in a mouse model of Parkinson's disease
- Open Access
LRRK2 G2019S promotes astrocytic inflammation induced by oligomeric α-synuclein through NF-κB pathway